ABIVAX Investor Relations Material
Latest events
Study Result
ABIVAX
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ABIVAX Société Anonyme
Access all reports
ABIVAX Société Anonyme is a clinical-stage biotechnology company that focuses on developing therapeutics designed to modulate the body's natural immune regulatory mechanisms. The company is primarily engaged in advancing its lead drug candidate, obefazimod, which is currently undergoing clinical trials aimed at treating moderately to severely active ulcerative colitis. Additionally, ABIVAX is exploring obefazimod's potential in treating other chronic inflammatory diseases, including Crohn's disease, through ongoing clinical trials and research initiatives. The company is headquartered in Paris, France, and its shares are listed on both the Nasdaq and the Euronext Paris.
Key slides for ABIVAX Société Anonyme
Corporate Presentation
ABIVAX Société Anonyme
Corporate Presentation
ABIVAX Société Anonyme
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ABVX
Country
🇫🇷 France